Dr Caroline Wilson

PhD, MRCP

School of Medicine and Population Health

Honorary Clinical Senior Lecturer

c.wilson@sheffield.ac.uk

The Medical School

Full contact details

Dr Caroline Wilson
School of Medicine and Population Health
The Medical School
Beech Hill Road
Sheffield
S10 2RX

Profile

For enquiries, please contact - SMPH-West-Operational@sheffield.ac.uk

Caroline graduated with distinction from Sheffield Medical School in 2002 and subsequently completed her junior doctor training in Sheffield, Australia and New Zealand. She began her higher specialist training in Medical Oncology in 2007 and in 2011 she took time out of her clinical training to carry out her PhD in Sheffield Medical School, focusing on the influence of hormones on breast cancer in the bone microenvironment.

After completing her PhD she was appointed as a consultant at Weston Park Cancer Hospital where she specialises in the treatment of breast cancer. Her research time is funded by Sheffield Teaching Hospitals NHS Foundation Trust and focuses on new therapies and therapeutic combinations for breast cancer and breast cancer bone metastases including immune-therapy. She has been primary author and co-author on multiple papers on breast cancer, bisphosphonates and bone metastases published in journals including the Lancet Oncology, Annals of Oncology, Clinical Cancer Research, JAMA oncology. She is also a reviewer for several journals.

Publications

Show: Featured publications All publications

Featured publications

Journal articles

Lee RJ, Wysocki O, Bhogal T, Shotton R, Tivey A, Angelakas A, Aung T, Banfill K, Baxter M, Boyce H , Brearton G et al (2021) Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO Open, 6(1).
George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25. View this article in WRRO
Wilson C, Martin C & Winter MC (2019) Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study. Journal of Bone Oncology, 15, 100226-100226.
Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94, 70-78.
Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D & Coleman RE (2016) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study. Journal of Bone Oncology. View this article in WRRO
Wilson C & Coleman R (2016) Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncology, 2(4), 423-423.
Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJA, Thomas G & Coleman RE (2016) Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. Journal of Bone Oncology, 5(1), 43-49. View this article in WRRO
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.
Wilson C, Ottewell P, Coleman RE & Holen I (2015) The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway. BMC Cancer, 15(1). View this article in WRRO
Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R , Barrett-Lee P et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15(9), 997-1006.
Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S , Holen I et al (2013) Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study. Clinical Cancer Research, 19(10), 2755-2765.
Wilson C, Holen I & Coleman RE (2012) Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treatment Reviews, 38(7), 877-889.

Chapters

Wilson C, Taylor FG & Coleman RE (2013) Toxicity of Bone-Targeted Agents in Malignancy, Side Effects of Medical Cancer Therapy (pp. 531-567). Springer London

All publications

Journal articles

Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C, Ali S & Holen I (2023) The CDK4/6 inhibitor palbociclib inhibits estrogen-positive and triple negative breast cancer bone metastasis in vivo. Cancers, 15(8). View this article in WRRO
Saxton JM, Pickering K, Wane S, Humphreys H, Crank H, Anderson AS, Cain H, Cohen J, Copeland RJ, Gray J , Hargreaves J et al (2022) Co-designed weight management intervention for women recovering from oestrogen-receptor positive breast cancer. BMC Cancer, 22(1).
JM S, K P, S W, H C, AS A, H C, J C, RJ C, J G, J H , RJQ M et al (2022) The experiences and perceptions of female breast cancer patients regarding weight management during and after treatment for oestrogen-receptor positive disease: a qualitative study. BMC Cancer, 22(1).
Kwan A, Howard F, Winder N, Atkinson E, Jailani A, Patel PB, Allen R, Ottewell PD, Shaw GC, Conner J , Wilson C et al (2022) Macrophage delivered HSV1716 is active against triple negative breast cancer. Future Pharmacology, 2(4), 444-459. View this article in WRRO
Winter M, Coleman R, Kendall J, Palmieri C, Twelves C, Howell S, MacPherson I, Wilson C, Purohit K, Gath J , Taylor C et al (2022) A phase IB and randomised phase IIA trial of CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases: CARBON trial results. Journal of Bone Oncology, 35, 100442-100442.
Lee RJ, Wysocki O, Zhou C, Shotton R, Tivey A, Lever L, Woodcock J, Albiges L, Angelakas A, Arnold D , Aung T et al (2022) Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital. JCO Clinical Cancer Informatics(6).
Boyce H, Rickards H & Wilson C (2022) Rapid Adaptation of Acute Oncology Services in One of the UK’s Largest NHS Foundation Trusts; Responding to COVID-19 and Beyond. Clinical Oncology, 34, e6-e7.
El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, Davies M, Desouza K, Dixon S, Hills D, Moe M , Pigott T et al (2021) Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer : a real-world multicentre UK study. The Breast, 60, 199-205. View this article in WRRO
Saleh L, Wilson C & Holen I (2021) CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer.. MedComm (2020), 2(4), 514-530.
Porter I, Theodoulou E, Holen I, Harper-Wynne C, Baron-Hay S, Wilson C & Brown J (2021) Adoption of adjuvant bisphosphonates for early breast cancer into standard clinical practice: Challenges and lessons learnt from comparison of the UK and Australian experience. Journal of Bone Oncology, 31, 100402-100402.
Canuas-Landero VG, George CN, Lefley DV, Corness H, Muthana M, Wilson C & Ottewell PD (2021) Oestradiol contributes to differential antitumour effects of adjuvant zoledronic acid observed between pre- and post-menopausal women. Frontiers in Endocrinology, 12. View this article in WRRO
El Badri S, Tahir B, Balachandran K, Bezecny P, Britton F, DeSouza K, Hills D, Moe M, Pigott T, Proctor A , Shah Y et al (2021) 245P Palbociclib combined with aromatase inhibitors (AIs) in women ≥75 years with oestrogen receptor positive (ER+ve), human epidermal growth factor receptor 2 negative (HER2-ve) advanced breast cancer: A real-world multicentre UK study. Annals of Oncology, 32, S466-S466.
Lee R, Wysocki O, Zhou C, Calles A, Eastlake L, Ganatra S, Harrison M, Horsley L, Huddar P, Khan K , Mckenzie H et al (2021) CORONET; COVID-19 in Oncology evaluatiON Tool: Use of machine learning to inform management of COVID-19 in patients with cancer.. Journal of Clinical Oncology, 39(15_suppl), 1505-1505.
Lee RJ, Wysocki O, Bhogal T, Shotton R, Tivey A, Angelakas A, Aung T, Banfill K, Baxter M, Boyce H , Brearton G et al (2021) Erratum to ‘Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome’. ESMO Open, 6(2), 100056-100056.
Canuas-Landero V, George C, Lefley D, Wilson C & Ottewell P (2021) Interactions between oestradiol and zoledronic acid in the bone microenvironment; physiological changes altering metastatic potential of breast cancer cells in pre- and post-menopausal women. Bone Reports, 14, 100899-100899. View this article in WRRO
George C, Lefley D, Canuas-Landero V, Tulotta C, Corness H, Wilson C, Muthana M & Ottewell P (2021) Differential effects of zoledronic acid and oestrogen on anti-cancer immunity. Bone Reports, 14, 101024-101024.
Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) Abstract PS14-02: A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. Cancer Research, 81(4_Supplement).
Pickering K, Wane S, Speake H, Crank H, Anderson A, Cain H, Copeland R, Lee D, Gray J, McNally R , Hargreaves J et al (2021) Abstract PS8-26: The new normal; adjusting to remote ways of providing bespoke weight management support to breast cancer survivors during the COVID-19 global pandemic. Cancer Research, 81(4_Supplement).
Badri SE, Hills D, Synowiec A, Harper-Wynne C, Moe M & Wilson C (2021) Abstract PS10-25: Tolerability and efficacy of palbociclib in combination with an aromatase inhibitor (AI) in older women (≥75 years) with ER +ve, HER2-ve metastatic breast cancer. A large ‘real world’ UK multi-centre study. Cancer Research, 81(4_Supplement).
Lee RJ, Wysocki O, Bhogal T, Shotton R, Tivey A, Angelakas A, Aung T, Banfill K, Baxter M, Boyce H , Brearton G et al (2021) Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome. ESMO Open, 6(1).
George CN, Canuas-Landero V, Theodoulou E, Muthana M, Wilson C & Ottewell P (2020) Oestrogen and zoledronic acid driven changes to the bone and immune environments: potential mechanisms underlying the differential anti-tumour effects of zoledronic acid in pre- and post-menopausal conditions. Journal of Bone Oncology, 25. View this article in WRRO
Lee R, Zhou C, Shotton R, Tivey A, Dickens E, Huddar P, McKenzie H, Boyce H, Maynard A, Rowe MP , Khan S et al (2020) 1690P Development of a model to predict hospital admission and severe outcome in cancer patients with COVID-19. Annals of Oncology, 31, S999-S999.
Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Abstracts: 2019 San Antonio Breast Cancer Symposium.
Saleh L, Wilson C & Holen I (2020) CDK4/6 inhibitors in breast cancer – from in vitro models to clinical trials. Acta Oncologica, 59(2), 219-232. View this article in WRRO
Ottewell P & Wilson C (2019) Bone-targeted agents in breast cancer : do we now have all the answers?. Breast Cancer: Basic and Clinical Research, 13. View this article in WRRO
Wilson C, Martin C & Winter MC (2019) Compliance and patient reported toxicity from oral adjuvant bisphosphonates in patients with early breast cancer. A cross sectional study. Journal of Bone Oncology, 15, 100226-100226.
Coleman RE, Collinson M, Gregory W, Marshall H, Bell R, Dodwell D, Keane M, Gil M, Barrett-Lee P, Ritchie D , Bowman A et al (2018) Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04). Journal of Bone Oncology, 13, 123-135. View this article in WRRO
Wilson C, Bell R, Hinsley S, Marshall H, Brown J, Cameron D, Dodwell D & Coleman R (2018) Adjuvant zoledronic acid reduces fractures in breast cancer patients; an AZURE (BIG 01/04) study. European Journal of Cancer, 94, 70-78.
Eslamian G, Wilson C & Young RJ (2017) Efficacy of eribulin in breast cancer: a short report on the emerging new data. OncoTargets and Therapy, Volume 10, 773-779. View this article in WRRO
Wilson C, Hinsley S, Marshall H, Cameron D, Bell R, Dodwell D & Coleman RE (2016) Reproductive hormone analyses and effects of adjuvant zoledronic acid in early breast cancer – An AZURE (BIG 01/04) sub-study. Journal of Bone Oncology. View this article in WRRO
Wilson C, Brown H & Holen I (2016) The endocrine influence on the bone microenvironment in early breast cancer.. Endocrine-Related Cancer. View this article in WRRO
Wilson C & Coleman R (2016) Adjuvant Bone-Targeted Therapies for Postmenopausal Breast Cancer. JAMA Oncology, 2(4), 423-423.
Wilson C, Gossiel F, Leonard R, Anderson RA, Adamson DJA, Thomas G & Coleman RE (2016) Goserelin, as an ovarian protector during (neo)adjuvant breast cancer chemotherapy, prevents long term altered bone turnover. Journal of Bone Oncology, 5(1), 43-49. View this article in WRRO
Wilson C (2016) Reproductive hormones in breast cancer bone metastasis: The role of inhibins. Journal of Bone Oncology, 5(3), 139-142.
Hadji P, Coleman RE, Wilson C, Powles TJ, Clézardin P, Aapro M, Costa L, Body J-J, Markopoulos C, Santini D , Diel I et al (2016) Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel. Annals of Oncology, 27(3), 379-390.
Silva SC, Wilson C & Woll PJ (2015) Bone-targeted agents in the treatment of lung cancer. Therapeutic Advances in Medical Oncology, 7(4), 219-228.
Wilson C, Ottewell P, Coleman RE & Holen I (2015) The differential anti-tumour effects of zoledronic acid in breast cancer – evidence for a role of the activin signaling pathway. BMC Cancer, 15(1). View this article in WRRO
Brown JE, Zeng L & Wilson C (2014) Bone Biomarkers in Research and Clinical Practice, 95-124.
Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R , Barrett-Lee P et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial. The Lancet Oncology, 15(9), 997-1006.
Wilson C, Khan M & Hancock BW (2013) Pharmacotherapy of gestational trophoblastic neoplasia. Expert Opinion on Orphan Drugs, 1(11), 877-890.
Coleman RE, Gregory W, Marshall H, Wilson C & Holen I (2013) The metastatic microenvironment of breast cancer: Clinical implications. The Breast, 22(Sup 2), S50-S56.
Winter MC, Wilson C, Syddall SP, Cross SS, Evans A, Ingram CE, Jolley IJ, Hatton MQ, Freeman JV, Mori S , Holen I et al (2013) Neoadjuvant Chemotherapy with or without Zoledronic Acid in Early Breast Cancer—A Randomized Biomarker Pilot Study. Clinical Cancer Research, 19(10), 2755-2765.
Coleman RE, Rathbone EJ, Marshall HC, Wilson C, Brown JE, Gossiel F, Gregory WM, Cameron D & Bell R (2012) Abstract S6-4: Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: an AZURE translational study.. General Session Abstracts.
Wilson C, Winter MC, Holen I, Freeman JV, Evans AC & Coleman RE (2012) Abstract P2-02-04: The interaction between menopausal status and zoledronic acid can differentially affect serum levels of the TGFβ superfamily.. Poster Session Abstracts.
Wilson C, Holen I & Coleman RE (2012) Seed, soil and secreted hormones: Potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treatment Reviews, 38(7), 877-889.
Wilson C & Coleman RE (2011) Adjuvant therapy with bone-targeted agents. Current Opinion in Supportive & Palliative Care, 5(3), 241-250.
Woll PJ, Wilson C, Leaning D, Shankland K, Langhenreich T & Batty R (2010) Cortical blindness as an unusual adverse drug reaction. Journal of Medical Case Reports, 1, 47-50.
Saxton JM & Wilson C () Tackling the adverse health effects of excess body fat in breast cancer: where does physical activity fit in?. Proceedings of the Nutrition Society, 1-17.
Wysocki O, Zhou C, Rogado J, Huddar P, Shotton R, Tivey A, Albiges L, Angelakas A, Arnold D, Aung T , Banfill K et al () An International Comparison of Presentation, Outcomes and CORONET Predictive Score Performance in Patients with Cancer Presenting with COVID-19 across Different Pandemic Waves. Cancers, 14(16), 3931-3931.
wilson () Standing the test of time in Europe? Gefitinib in the treatment of non-small-cell lung cancer. Lung Cancer: Targets and Therapy, 37-37.
Wilson C, Nutter F, Brown H, Coleman R & Holen I () Effects of the female hormone inhibin-A in vivo: potential contribution to the antitumour effect of Zoledronic acid. Bone Abstracts.

Chapters

Wilson C, Taylor F & Coleman R (2018) Toxicity of Bone-Targeted Agents in Malignancy, Side Effects of Medical Cancer Therapy (pp. 439-460). Springer International Publishing
Wilson C, Taylor FG & Coleman RE (2013) Toxicity of Bone-Targeted Agents in Malignancy, Side Effects of Medical Cancer Therapy (pp. 531-567). Springer London
Wilson C & Hancock BW (2009) The role of human chorionic gonadotropin (HCG) in gestational trophoblastic disease, Pregnancy Protein Research (pp. 135-147).

Conference proceedings papers

El Badri S, Hills D, Synowiec A, Harper-Wynne C, Moe M & Wilson C (2021) Tolerability and efficacy of palbociclib in combination with an aromatase inhibitor (AI) in older women (≥75 years) with ER +ve, HER2-ve metastatic breast cancer. A large 'real world' UK multi-centre study. CANCER RESEARCH, Vol. 81(4)
Pickering K, Wane S, Speake H, Crank H, Anderson A, Cain H, Copeland R, Lee D, Gray J, McNally R , Hargreaves J et al (2021) The new normal; adjusting to remote ways of providing bespoke weight management support to breast cancer survivors during the COVID-19 global pandemic. CANCER RESEARCH, Vol. 81(4)
Winter M, Kendall J, Brown S, Rathbone E, Wilson C, Howell S, Twelves C, Palmieri C, Anand A, MacPherson I , Coleman R et al (2021) A randomised phase IB/IIA study of CApecitabine plus Radium-223 in breast cancer patients with BONe metastases (CARBON) - Safety and preliminary efficacy findings. CANCER RESEARCH, Vol. 81(4)
Baron-Hay S, Theodoulou E, Porter I, Wilson C, Holen I, Harper-Wynne C & Brown J (2020) Abstract P2-18-08: Inclusion of adjuvant bone-modifying agents for early breast cancer into standard clinical practice: Challenges and lessons learnt from an international collaboration. Poster Session Abstracts
Saleh L, Ottewell PD, Brown JE, Wood SL, Brown NJ, Wilson C, Park C & Holen I (2020) Preventing the progression of breast cancer bone metastasis by CDK inhibition. BREAST CANCER RESEARCH AND TREATMENT, Vol. 180(2) (pp 537-538)
Ghazi S, Monawer Karim S, Wilson C & Martin C (2018) Can Everolimus in Combination with Exemestane, for Metastatic Breast Patients, be Delivered in a Health Care Professional Led Clinic. A Retrospective Service Evaluation from a South Yorkshire Population. Clinical Oncology, Vol. 30(6) (pp e44-e44)
Wilson C, Taylor F & Woll PJ (2010) An audit of the use and utility of erlotinib at Weston Park Hospital, Sheffield UK. Lung Cancer, Vol. 67 (pp S5-S6)